Barree Posted September 10, 2017 Share Posted September 10, 2017 The long awaited trial results of the phase II trials at Peter Mac were presented at the ESMO European Society Medical Oncologists over the weekend,8th & 9th of September 2017. Near on 23000 participants from 131 Countries are in attendance at the conference. Dr. Hofman and colleagues from Melbourne, Australia presented results from their phase II Lutetium-177 PSMA trial for the treatment of metastatic castrate-resistant prostate cancer. This treatment provides an opportunity for new therapeutic technology to be used to improve survival. Another interesting article presented at the same session was Targeted Alpha Therapy(TAT) by Professor Johann de Bono from the UK He discussed the future of targeted alpha therapy. Dr. de Bono shared a comprehensive slide delineating the timeline of alpha-emitting radionuclide therapy in oncology, specifically highlighting radium-223 approval in mCRPC in 2013 and the first patient being treated with Thorium-227 in 2016. The study conclusion: In conclusion, this phase II trial demonstrates that 177Lu-PSMA treatment for patients with mCRPC who have failed standard therapy provides encouraging response rates with acceptable toxicity, in addition to improved QoL and pain reduction. Based on this trial, we eagerly await the results of larger studies with long-term follow-up. This information is on the URO Today site.. Lutetium Trial Results September 2017 ESMO (This is on UroToday. It is only available to UroToday members, so you will have to join up to see it. Joining is free.) countries are attending the 2017 Congress, being held 8 to 12 September in Madrid 23,000 participants from 131 countries are attending th2017 Congress, being held 8 to 12 September in Madrid Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.